Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy

Journal of Geriatric Cardiology

Volumn 10, Issue 3, 2013, Pages 286-290

  Li, Xin ^a   Zhu, Hang ^a   Li, Peng ^a   Xin, Qian ^a   Liu, Jie ^a   Zhang, Wei ^a   Xing, You Hong ^a   Xue, Hao ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cystatin C; Hypertension; Left ventricular hypertrophy

Indexed keywords

CYSTATIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE WALL; HEART WEIGHT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

EID: 84885787769     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2013.03.001     Document Type: Article

References (28)

1. Aumann N, Baumeister SE, Werner A, et al. Inverse association of estimated cystatin C- and creatinine-based glomerular filtration rate with left ventricular mass: Results from the Study of Health in Pomerania. Int J Cardiol 2013; 167: 2786-2791.
2. Mathew J, Katz R, St John Sutton M, et al. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail 2012; 14: 1420-1428.
3. Park M, Hsu CY, Li Y, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. Chronic Renal Insufficiency Cohort (CRIC) Study Group. J Am Soc Nephrol 2012; 23: 1725-1734.
4. Kilic T, Oner G, Ural E, et al. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 2009; 207: 552-558.
5. Shin MJ, Song SH, Kwak IS, et al. Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis. Clin Exp Nephrol 2012; 16: 456-463.
6. Pérez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sánchez FJ, et al. Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur J Intern Med 2012; 23: 599-603.
7. Monteiro Junior Fd, Ferreira PA, Nunes JA, et al. Correlation between serum cystatin C and markers of subclinical atherosclerosis in hypertensive patients. Arq Bras Cardiol 2012; 99: 899-906.
8. Dupont M, Wu Y, Hazen SL, et al. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail 2012; 5:602-609.
9. Prats M, Font R, Bardají A, et al. Cystatin C and cardiac hypertrophy in primary hypertension. Blood Press 2010; 19: 20-25.
10. Tousoulis D, Androulakis E, Papageorgiou N, et al.Genetic predisposition to left ventricular hypertrophy and the potential involvement of cystatin-C in untreated hypertension. Am J Hypertens 2013; 26: 683-690.
11. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
12. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
13. Ozden TA, Tekerek H, Baş F, et al. Effect of hypo-and euthyroid status on serum cystatin C levels. J Clin Res Pediatr Endocrinol 2010; 2: 155-158.
14. Gluba A, Bielecka A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens 2012; 30: 1681-1689.
15. Kampoli AM, Tousoulis D, Papageorgiou N, et al. Clinical utility of biomarkers in premature atherosclerosis. Curr Med Chem 2012; 19: 2521-2533.
16. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
17. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173-179.
18. Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrast- induced acute kidney injury. Circulation 2010; 121: 2117-2122.
19. Trof RJ, Di Maggio F, Leemreis J, et al. Biomarkers of acute renal injury and renal failure. Shock 2006; 26: 245-253.
20. Odutayo A, Cherney D. Cystatin C and acute changes in glomerular filtration rate. Clin Nephrol 2012; 78: 64-75.
21. Ozer BA, Dursun B, Baykal A, et al. Can cystatin C be a better marker for the early detection of renal damage in primary hypertensive patients? Ren Fail 2005; 27: 247-253.
22. Julien J, Tranche C, Souchet T. Left ventricular hypertrophy in hypertensive patients. Epidemiology and prognosis. Arch Mal Coeur Vaiss 2004; 97: 221-227.
23. Coca A, De la Sierra A. Salt sensitivity and left ventricular hypertrophy. Adv Exp Med Biol 1997; 432: 91-101.
24. Cheng XW, Obata K, Kuzuya M, et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006; 48: 979-987.
25. Bengtsson E, Nilsson J, Jovinge S. Cystatin C and cathepsins in cardiovascular disease. Front Biosci 2008; 13: 5780-5786.
26. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009; 55: 1932-1943.
27. Cheng XW, Kuzuya M, Nakamura K, et al. Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. Am J Pathol 2006; 168: 685-694.
28. Xie L, Terrand J, Xu B, et al. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res 2010; 87: 628-635.